Alzheimer disease (AD) is the most common contributor to dementia in the world, but
strategies that slow or prevent its clinical progression have largely remained elusive, until …

Blood‐based markers (BBMs) have recently shown promise to revolutionize the diagnostic
and prognostic work‐up of Alzheimer's disease (AD), as well as to improve the design of …

Blood biomarkers indicating elevated amyloid-β (Aβ) pathology in preclinical Alzheimer's
disease are needed to facilitate the initial screening process of participants in disease …

Blood biomarkers indicative of Alzheimer's disease (AD) pathology are altered in both
preclinical and symptomatic stages of the disease. Distinctive biomarkers may be optimal for …

An unresolved question for the understanding of Alzheimer's disease (AD) pathophysiology
is why a significant percentage of amyloid-β (Aβ)-positive cognitively unimpaired (CU) …

Blood-based biomarkers hold great promise to revolutionize the diagnostic and prognostic
work-up of Alzheimer's disease (AD) in clinical practice. This is very timely, considering the …

Neurodegenerative disorders such as Alzheimer's disease (AD) represent a mounting public
health challenge. As these diseases are difficult to diagnose clinically, biomarkers of …

Several promising plasma biomarkers for Alzheimer's disease have been recently
developed, but their neuropathological correlates have not yet been fully determined. To …

Importance Plasma biomarkers of Alzheimer disease may be useful as minimally invasive
pharmacodynamic measures of treatment outcomes. Objective To analyze the association of …

Recent Aβ-immunotherapy trials have yielded the first clear evidence that removing
aggregated Aβ from the brains of symptomatic patients can slow the progression of …